For research and educational purposes only. Not medical advice.
Vilon Reference
Educational, not medical advice reference for Vilon: Longevity, Immune; regulatory status, evidence posture, source review, and schedule notes. Also known as…
Reference summary
Public evidence is preclinical and older, including mouse spontaneous-tumor / lifespan work and compound registry records. Human outcome data are not established.
- Categories
- Longevity, Immune
- Aliases
- Lys-Glu, KE dipeptide, Lysylglutamic acid
- Evidence posture
- preclinical — Preclinical dipeptide. Longevity and anticancer community claims are unproven and should not be read as treatment evidence.
- Regulatory status
- No FDA-approved Vilon drug label. Vilon is a synthetic dipeptide from the Russian peptide-bioregulator literature and is not an FDA-reviewed longevity, immune, or oncology product.
- Content review status
- research reference